BIND Therapeutics, Inc.

325 Vassar St.

Cambridge, MA  02139

Tel: 617.491.3400

Scott Minick
President & CEO



BIND Therapeutics, Inc.

Flagship Partners:  Noubar Afeyan
Initial Investment: 

BIND Therapeutics (NASDAQ: BIND) is a publicly traded clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its medicinal nanoengineering platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND's lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate resistant prostate cancer.

Noubar Afeyan is on the Board of Directors.